School Of Health Sciences

Permanent URI for this communityhttps://kr.cup.edu.in/handle/32116/102

Browse

Subject: search.filters.subject.Drug delivery

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Neurodegenerative diseases and brain delivery of therapeutics: Bridging the gap using dendrimers
    (Editions de Sante, 2023-08-26T00:00:00) Kaur, Amandeep; Singh, Navneet; Kaur, Harmanpreet; Kakoty, Violina; Sharma, Deep Shikha; Khursheed, Rubiya; Babu, Molakpogu Ravindra; Harish, Vancha; Gupta, Gaurav; Gulati, Monica; Kumar, Puneet; Dureja, Harish; Alharthi, Nahed S.; Khan, Farhan R.; Rehman, Zia ur; Hakami, Mohammed Ageeli; Patel, Mrunali; Patel, Rashmin; Zandi, Milad; Vishwas, Sukriti; Dua, Kamal; Singh, Sachin Kumar
    Neurodegenerative diseases (NDs) continue to burden human lives and economic conditions. They continue to challenge the healthcare system due to the associated physiological barriers. Traditional treatment approaches are associated with symptomatic relief and are ineffective in the long run. Dendrimers stand out amongst other nanocarriers due to ease of surface modifications, internal encapsulation, and nanoscale uniformity of the molecule. Moreover, their internal core can encapsulate drug through electrostatic interactions. These are stable carriers in the nanometer size range. These either act as therapeutic agents per se or deliver the target drug across the blood-brain barrier while minimizing toxicity. Emerging as a promising non-invasive approach, they demonstrate the capability to interfere with in-vivo protein aggregation, typically associated with neurodegeneration. They assist via exerting various neuroprotective roles, such as in oxidative stress, neuroinflammation, inhibiting certain biochemical parameters, altering protein misfolding and aggregation, etc. However, certain limitations are associated with their elimination and cytotoxicity. The investigation revealed the masking of exposed cationic surfaces of dendrimers with inert substances, such as polyethylene glycol to limit their cytotoxicity. This review describes the incidences and pathophysiology of several NDs, properties, and methods of dendrimer synthesis, followed by various research to explore dendrimers potential to treat NDs. � 2023 Elsevier B.V.
  • No Thumbnail Available
    Item
    Biomedical applications of polysaccharide nanoparticles for chronic inflammatory disorders: Focus on rheumatoid arthritis, diabetes and organ fibrosis
    (Elsevier Ltd, 2021-11-22T00:00:00) Allawadhi, Prince; Singh, Vishakha; Govindaraj, Kannan; Khurana, Isha; Sarode, Lopmudra P.; Navik, Umashanker; Banothu, Anil Kumar; Weiskirchen, Ralf; Bharani, Kala Kumar; Khurana, Amit
    Polysaccharides are biopolymers distinguished by their complex secondary structures executing various roles in microorganisms, plants, and animals. They are made up of long monomers of similar type or as a combination of other monomeric chains. Polysaccharides are considered superior as compared to other polymers due to their diversity in charge and size, biodegradability, abundance, bio-compatibility, and less toxicity. These natural polymers are widely used in designing of nanoparticles (NPs) which possess wide applications in therapeutics, diagnostics, delivery and protection of bioactive compounds or drugs. The side chain reactive groups of polysaccharides are advantageous for functionalization with nanoparticle-based conjugates or therapeutic agents such as small molecules, proteins, peptides and nucleic acids. Polysaccharide NPs show excellent pharmacokinetic and drug delivery properties, facilitate improved oral absorption, control the release of drugs, increases in vivo retention capability, targeted delivery, and exert synergistic effects. This review updates the usage of polysaccharides based NPs particularly cellulose, chitosan, hyaluronic acid, alginate, dextran, starch, cyclodextrins, pullulan, and their combinations with promising applications in diabetes, organ fibrosis and arthritis. � 2021 Elsevier Ltd